CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 151 enrolled
Drug / intervention
ST266 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02761993
NCT02761993Phase 2Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Treatment Regimen of ST266 in Subjects With Moderate to Severe Periodontitis

Noveome Biotherapeutics, formerly Stemnion·interventional·Posted May 4, 2016·Updated Jul 22, 2021

In Brief

A Phase 2 clinical trial evaluating ST266 and Saline (0.9% NaCl) for Periodontal Disease. Completed, enrolled 151 participants across 6 sites.

Detailed Summary

The purpose of this study is to determine whether ST266 will reduce pocket depth (PD) as an adjunctive to scaling and root planing (SRP) in subjects with moderate to severe periodontal disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeriodontal Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 4, 2016
Enrollment StartApr 1, 2016
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.2 years ago

Interventions

ST266biological

1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).

Saline (0.9% NaCl)drug

Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).